gdc

Leukemia

Leukemia
People with chronic lymphocytic leukemia (CLL) can experience improvements in the way their care is managed by using a free telehealth program that connects patients with doctors who specialize in the disease.
Leukemia
Today, more people, including patients diagnosed with chronic lymphocytic leukemia, are living longer with cancer thanks to advancements in cancer treatments. Improvements in the chance for long-term cancer remission are clearly important but living with cancer can also bring a new set of challenges.
Leukemia
People with cancer, including people who have been diagnosed with chronic lymphocytic leukemia, do not need to face it alone. Valuable online and local resources are available for patients with cancer and their loved ones.
Leukemia
For many patients with chronic lymphocytic leukemia (CLL), treatment is personalized. This means that oncologists tailor their medication choices based on the patient’s unique CLL characteristics and medical status.
Leukemia
Targeted therapies are effective in controlling chronic lymphocytic leukemia (CLL). New research is now looking into the impact that these agents can have on autoimmune conditions.
Leukemia
A new type of immunotherapy, allogeneic cord blood–derived CAR NK-cells, could be a future option for patients with chronic lymphocytic leukemia (CLL), based on results from an early-phase clinical trial showing high response rates among patients.
First-Line Calquence-Based Combination Therapy for Patients with Chronic Lymphocytic Leukemia
Leukemia
Calquence, a new-generation targeted therapy recently approved for the treatment of CLL, has shown good results in a 3-drug combination therapy.
Brukinsa, a New BTK Inhibitor, Shows Impressive Results in Patients with CLL
Leukemia
Brukinsa, which was approved for use in patients with mantle-cell leukemia in late 2019, has also showed promising results in 2 recent clinical trials of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities.
New All-Oral Combination Therapy for CLL Shows Impressive Results
Leukemia
A new study using a combination of the 2 oral drugs, Copiktra and Venclexta, showed promising results for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Leukemia
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials.
Page 2 of 7
Results 11 - 20 of 62

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country